27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Eli Lilly And Co (NYSE:LLY) announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for HR-positive, HER2-negative high-risk early breast cancer.
- The new data showed Verzenio’s benefits held up across patient subgroups after longer follow-up.
- Also read: Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage.
- In 2020, The monarchE trial hit statistical significance after a median of 15.5 months follow-up. Verzenio’s addition to post-surgery endocrine therapy significantly cut the risk of invasive cancer recurrence or death by 25%, regardless of Ki-67 status.
- Now, investigators have followed patients for a median of 42 months, coming to the second preplanned interim analysis of patient survival. Nearly all patients had already come off the two-year treatment period.
- In the overall population, the Verzenio group had a 33.6% reduced risk of developing invasive disease recurrence or death over the control arm, which got endocrine therapy alone.
- Adjuvant Verzenio also reduced the risk of developing the metastatic disease by 34.1%.
- Price Action: LLY shares are up 0.26% at $369.25 on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!